Phase III Oncology: Targeted Risk-Based QA Case Study

How ADAMAS used AI-augmented RBQM analytics to strengthen oversight, focus QA effort, and improve inspection readiness in a global Phase III oncology study.

Phase III Oncology: Targeted Risk-Based QA Case Study

How ADAMAS used AI-augmented RBQM analytics to strengthen oversight, focus QA effort, and improve inspection readiness in a global Phase III oncology study.
Cyntegrity logo – Risk-Based Quality Management Solutions

Targeted Risk-Based QA with AI-Augmented Oversight

In late-phase oncology, inspection readiness depends on how reliably teams can detect meaningful risk signals across large volumes of study data. In this collaboration, ADAMAS Consulting combined its QA expertise with Cyntegrity’s AI-augmented analytics to strengthen oversight across a global Phase III program.

 

Using the MyRBQM® Portal, ADAMAS applied targeted risk indicators to centrally review data from 50 investigator sites. Early signal detection enabled QA to focus on locations where data integrity or patient safety were most at risk—directly supporting the principles of ICH E6(R3).

 

This targeted approach helped the sponsor act sooner, prepare more effectively for inspection, and strengthen confidence in overall study quality.

What This Case Study Demonstrates

1
2
3
1

Focused QA Where It Has the Most Impact

Risk indicators highlighted site patterns early, enabling QA teams to direct their efforts to high-value areas instead of conducting broad, low-return reviews.

2

Central Monitoring That Accelerates Corrective Action

Data anomalies and outliers surfaced sooner, allowing corrective steps to be initiated earlier in the study lifecycle.

3

Inspection Readiness in Complex Oncology Studies

Transparent, centralized insight supported a clearer rationale for QA decisions—strengthening inspection narratives and reducing pre-inspection workload.

Partnering for Better Oversight

Cyntegrity provides the AI-augmented RBQM technology through the MyRBQM® Portal.

 

ADAMAS contributes deep QA expertise and strategic guidance.

 

Together, they help oncology sponsors reduce oversight burden, detect issues earlier, and approach inspections with strengthened confidence.

ADAMAS Consulting used AI-supported RBQM analytics to prioritize QA focus across 50 sites, accelerating early risk detection and improving inspection readiness.

ADAMAS Consulting used AI-supported RBQM analytics to prioritize QA focus across 50 sites, accelerating early risk detection and improving inspection readiness.

Download the Full Case Study

Learn how ADAMAS supported a leading oncology sponsor using an AI-augmented, risk-based QA model.

Stay Informed with Us

Risk-based quality management in 2026

Risk-based quality management in 2026: how ICH E6(R3) defines RBQM, where practice diverges, and what regulators now expect in clinical trials....
Diagram illustrating the FDA Total Product Lifecycle (TPLC) management approach for AI and machine learning devices, showing a continuous cycle of design, validation, submission, monitoring, and update.

FDA AI Guidance 2025 Interactive Visualizer

Explore how FDA’s 2025 AI guidance shapes lifecycle oversight for AI-enabled medical software through interactive regulatory scenarios....

Media Inquiries

Need a quote, speaker, or more info about Cyntegrity? Reach out directly to our media contact for timely assistance.

Phase III Oncology RBQM Case Study

Phase III Oncology RBQM Case Study